Eli Lil­ly’s mirik­izum­ab joins the club beat­ing up on Cosen­tyx as an­oth­er head-to-head study leaves No­var­tis’ drug in the dust

Eli Lil­ly’s high hopes for its IL-23 an­ti-in­flam­ma­to­ry drug mirik­izum­ab were borne out by a suc­cess­ful round of Phase III da­ta demon­strat­ing its su­pe­ri­or­i­ty to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.